John G. Houston, Ph.D.
Dr. Houston is President and Chief Executive Officer of Arvinas. Previously, he was the SVP of Specialty Discovery at Bristol-Myers Squibb (BMS). He spent more than 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments. He was also the site head of the BMS Connecticut facility. Dr. Houston was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee which had governance oversight in the discovery space. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late stage clinical trials, and toward commercialization.
He was also the principal architect and driver of the ‘Leveraging Technology’ initiative at BMS which oversaw the design and implementation of an industry-leading integrated lead discovery and optimization process. This initiative created revolutionary changes in the discovery process at BMS with significant improvements in capacity, speed and cost control resulting in marked increases in research productivity and success rates.
Dr. Houston has over 28 years of experience in the pharmaceutical industry. Prior to joining Bristol-Myers Squibb, he worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead Discovery Unit.
Dr. Houston obtained his B.Sc degree in Medical Microbiology from Glasgow University and obtained his Ph.D. with Professor Brian Catley in Microbial Biochemistry from Heriot-Watt University, Edinburgh. He also completed his post-doctoral studies on an MRC grant with Professor Julia Douglas at Glasgow University.
Matthew Batters, J.D.
Mr. Batters is Vice President, Business Development & Counsel, and is responsible for Arvinas’s business development, alliance management, and legal functions.
Previously, Mr. Batters was a Senior Director at Alexion Pharmaceuticals, where he was responsible for licensing, collaborations and M&A activities.
Prior to Alexion, Mr. Batters was an associate at each of DLA Piper and Skadden, Arps, Slate, Meagher & Flom, where he advised biopharmaceutical clients on a wide range of licensing, collaborations, and M&A transactions as well as capital raising and securities matters.
Mr. Batters received a JD from Columbia Law School, an M.A. from the University of London and a B.A. from the University of Bristol.
Angela M. Cacace, Ph.D.
Dr. Cacace is the Vice President of Neuroscience and Platform Biology at Arvinas. Angela brings more than two decades of biopharmaceutical research and pharmacology experience, contributing to four marketed drugs and over 18 development candidates. Angela came to the company after serving as the Vice President of Biology at Fulcrum Therapeutics, where, together with her team, she built the biology platform and delivered the first development candidate for the treatment of FSHD. Previously, Angela was the Director of Neuroscience and Genetically Defined Diseases at Bristol-Myers Squibb where she spearheaded alternative therapeutic modalities and was a coinventor on several development candidates.
Throughout her 19 years at Bristol-Myers Squibb, she has held multiple leadership positions, where she was responsible for building research-wide teams and initiatives including the Lead Profiling Function, GPCR High Throughput Screening Team and the Cellular Resource Team. While serving as a Sr. Principal Scientist in Cancer Biology at Pfizer, together with her team, she discovered a novel anti-angiogenic antibody development candidate.
Angela received her B.S. in biology from Fairfield University, Ph.D. in pharmacology from Columbia University and completed her postdoctoral research in Oncology at Bristol-Myers Squibb and the National Cancer Institute.
Sean Cassidy, M.B.A., C.P.A.
Mr. Cassidy is the Chief Financial Officer of Arvinas. He has over 20 years of experience in the life sciences industry, including serving as Chief Financial Officer of Axerion Therapeutics, a preclinical biotechnology company developing therapies for neurological diseases and injuries; Chief Financial Officer of CuraGen Corporation (NASDAQ: CRGN), a clinical stage biopharmaceutical company; and Director and Controller of 454 Life Sciences Corporation, a life sciences company that developed and commercialized next generation DNA sequencing instruments and reagents.
Earlier in his career, Mr. Cassidy served at Deloitte, one of the big four public accounting firms with a broad base of clients in the healthcare space. Mr. Cassidy is also the Treasurer of the Friends of Yale New Haven Children’s Hospital, a nonprofit organization that helps improve the health and well-being of pediatric patients and their families.
Mr. Cassidy holds an M.B.A. and B.S. from the University of Connecticut and is a Certified Public Accountant in the State of Connecticut.
John A. Grosso, Ph.D.
Dr. Grosso is the Vice President of Chemistry, Manufacturing, and Controls at Arvinas. He brings over 35 years of broadly diversified pharmaceutical development and manufacturing experience to the Company, having led process chemistry, analytical, and drug development functions both in large pharma and in biotech.
Prior to joining Arvinas, Dr. Grosso was Executive Director and Head of Pharmaceutical Development at Vitae Pharmaceuticals where he was responsible for API and DP development and manufacturing as well as Clinical Supply. During the two years spent at Vitae, he advanced two oral RORƴt antagonists and one LXR agonist into the clinic.
Dr. Grosso began his career with Bristol-Myers Squibb in Chemical Process R&D rising to the level of Director and site-head for PR&D over a twenty-year span. He transitioned into Analytical R&D where, as Executive Director, he was responsible for process analytical science, method development and testing for both API and DP, in addition to a number of specialty labs. He finished his tenure at BMS as Executive Director, Drug Product Science and Technology. Over his 32-year career at BMS he played a pivotal role in the development and commercialization of Monopril®, Taxol®, Eliquis®, Sprycel®, and Dapagliflozin®
Dr. Grosso earned his undergraduate degree in Chemistry at New York University, and his Ph.D. in Medicinal Chemistry at Purdue University.
Marcia Dougan Moore, M.P.H.
Ms. Dougan Moore is the Vice President of Development Operations at Arvinas. She has more than 25 years of experience in the pharmaceutical and biotechnology industries, and is currently a member of the Product Development Peer Review Committee at the Cancer Prevention and Research Institute of Texas. Over the course of her career, Ms. Dougan Moore has worked across all phases of drug development including IND-enabling activities, clinical trials (Phases 1-3) and in the post-marketing setting. Previously, she served as Director, Strategic Drug Development and Project Management at Alexion Pharmaceuticals, where she successfully transitioned products into clinical development. Ms. Dougan Moore was also a key contributor to the success of several regulatory filings.
She began her career at Bristol-Myers Squibb where she held positions of increasing responsibility in clinical research, new market planning and external development. She was also a member of the Bristol-Myers Squibb Foundation’s Oncology Unrestricted Grants Committee.
Ms. Dougan Moore received her M.P.H. from Yale University and B.S. from Bates College.
Ron Peck, M.D.
Dr. Ron Peck is Chief Medical Officer at Arvinas. Dr. Peck brings more than twenty years of clinical and drug development experience, most recently serving as Senior Vice President, Clinical Research at Tesaro, where he oversaw all clinical development efforts for the company’s entire pipeline, including Zejula® (niraparib) and Tesaro’s immuno-oncology programs. Prior to his work at Tesaro, Dr. Peck served as the CMO of Kolltan Pharmaceuticals, a privately held clinical-stage biotech where he oversaw the clinical development of monoclonal antibodies targeting receptor tyrosine kinases. Dr. Peck began his industry career at Bristol Myers Squibb (BMS), where he spent 15 years in drug development, eventually serving as Vice President, YERVOY® (ipilimumab) Global Development Lead. At BMS, he played a key role in the approval and commercialization of YERVOY® (ipilimumab) across all indications and contributed to the successful development of multiple other oncology assets, including IXEMPRA® (ixabepilone). Early in his BMS career, Dr. Peck contributed to the life cycle development of ABILIFY® (aripiprazole) within the neuroscience clinical research organization. Dr. Peck received his bachelor’s degree in chemistry from Georgetown University in Washington, D.C., his M.D. from Thomas Jefferson University Medical College in Philadelphia, PA., and completed a residency and hematology/oncology fellowship at Georgetown University in Washington, D.C before serving as Assistant Professor of Medicine at the University of Virginia.
Ian Taylor, Ph.D.
Dr. Taylor is the Chief Scientific Officer at Arvinas. He came to the Company after nearly 10 years at Pfizer Oncology, most recently as an Early Development Team Leader. In this role, Dr. Taylor was responsible for leading a cross-functional drug development team that conducted Phase 1 and Phase 2 clinical trials for multiple assets in several cancer indications. His initial role at Pfizer Oncology was as Senior Director of Translational Oncology. In this role, he was responsible for directing translational science activities, which included designing and executing translational research plans and leading companion diagnostic partnerships for programs in both preclinical and clinical (Phase 1 -3) stages.
Prior to Pfizer, Dr. Taylor worked at Bayer Healthcare, Pharmaceuticals, holding positions of increasing responsibility including Vice President of Cancer Biology. In this position, he led the department responsible for all biology aspects of small molecule drug discovery of cancer therapeutics in the mechanistic areas of signal transduction, cell cycle regulation, angiogenesis and apoptosis. During his tenure, the Cancer Biology group delivered numerous molecules to the Development organization. He also started and led the Biomarker group, which contributed to the development of sorafenib.
Dr. Taylor earned his B.A. from Bowdoin College and his Ph.D. in Molecular Biology and Genetics from Harvard University. He also completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco and the National Institutes of Health (NIH).
Randy Teel, Ph.D.
Dr. Teel is Vice President, Corporate Development, and is responsible for our corporate strategy, investor relations, and commercial development functions.
Previously, Dr. Teel was VP and Head of Strategy at Alexion Pharmaceuticals, where he was responsible for long-range planning, partnering with the R&D and Commercial organizations as they developed inline and lifecycle management strategies. Dr. Teel also led enterprise risk management and numerous strategic initiatives across the company.
Prior to Alexion, Dr. Teel was an Associate Partner at McKinsey & Company, where he advised biopharmaceutical clients on issues in commercial, medical, and development He also served numerous other clients in the healthcare industry, including device manufacturers, insurers, and pharmaceutical distributors.
Dr. Teel is on the board of Integrated Refugee & Immigrant Services (IRIS) and is board treasurer for Neighborhood Music School, both of which are not-for-profits in New Haven, CT.
Dr. Teel received a Ph.D (Immunobiology) from Yale University and a B.S. (Biology) from Gonzaga University.
Ms. Wehger is the Vice President, Information Technology at Arvinas. She has over 15 years of experience in information technology specific to the life sciences industry.
Prior to joining Arvinas, Ms. Wehger served as Practice Manager, R&D Managed Services at Veeva Systems, an organization focused on long-term, post-implementation consulting to Veeva Vault customers. Previously, she was Vice President and CIO at New Haven Pharmaceuticals, a Connecticut-based pharmaceutical start-up focused primarily on cardiovascular disease. Earlier in her career, she was Director of Business Engagement in the IT department of Alexion, leading the globally-distributed Business Analysis, Application Administration, and Development teams, and she held roles of increasing responsibility at Purdue Pharma.
Ms. Wehger received her B.A. from Binghamton University and her M.A. from Southern Connecticut State University.
Mr. Weiss is the VP, Human Resources at Arvinas and he is responsible for overseeing all aspects of human resources, including Talent Acquisition, Total Rewards, Organization and Leadership Development, Diversity and Inclusion, and Engagement. He is a business-focused, results oriented individual with over 25 years of global experience in diverse industries including biotechnology, diagnostic imaging, asset management, legal and financial services.
Most recently, Mr. Weiss served as Executive Director, Human Resources at Alexion Pharmaceuticals. In this role, he led the delivery of strategic human resource programs and solutions across multiple corporate functions including Finance, IT, Legal, Compliance, Government Affairs, Business Development and Strategy. Prior to Alexion Pharmaceuticals, Mr. Weiss was Assistant Vice President with Hartford Investment Management and he held roles of increasing responsibility previously at United Technologies, General Electric and Sullivan & Cromwell.
Mr. Weiss holds a B.S. degree from the University of Kansas.